lobbying_activities: 1847598

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1847598	fd7695bd-07d2-4194-9dda-61ae50c12fb5	Q2	APOTEX CORP.	310973	APOTEX CORP.	2016	second_quarter	PHA	H.R. 2841, The FAST Generics Act of 2015, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing; S. 3056, the CREATES Act, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing; Federal policy relating to the approval of pending abbreviated new drug applications for generic versions of Crestor; and S. 1137, The Patent Act, Technical corrections to the Leahy-Smith American Invents Act and other improvements, provisions in Section 14 relating to the inter partes review process, including federal policy relating to the use of inter partes review challenges of pharmaceutical and biotechnology patents.	HOUSE OF REPRESENTATIVES,SENATE		230000	0	0	2016-07-18T18:14:24.943000-04:00